Heberprot-P, A Cuban Biotechnology Example to the World

Havana, Apr 2 (Prensa Latina) Heberprot-P has become in the last three years the leader product of the Cuban Center of Genetic Immunology and Biotechnology (CIGB), experts of the sector told the news agency Prensa Latina today.

Doctor Carlos Mella, expert in Market Intelligence of the Marketing Company of Biotechnological and Pharmaceutical Products of the CIGB, Heber-Biotec, said the medicine made the difference at international level.

Heber-Biotec, founded in 1991, is one of the speakers at the 2nd International Conference Technology and Health, with Havana’s Conference Center as venue.

Heberprot-P is used to treat piercing ulcers on diabetic foot, an injury really hard to fight, at the extent that most patients with this injury lose their affected leg.

Mella explained that before having the mentioned medicine, the CIGB worked on other research lines. The closest treatment to skin ulcers was an cream, only for external use that is still produced today, but used for burns and related injuries.

Arts graduate Carmen Marrero, sales manager of the division of European countries at Heber-Biotec, reported to Prensa Latina that Heberprot-P had been already registered in 19 Latin American countries, North Africa and Asia.

sgl/iom/ale/nvo

Modificado el ( miƩrcoles, 02 de abril de 2014 )
Advertisements

High Life Expectancy for Diabetic Patients in Cuba

Havana, Cuba, Apr 1.- Eighty-four percent of Cubans with diabetes mellitus have a life expectancy of nearly 78 years, similar to that of those who have not suffered the disease, the Granma newspaper reported today.

According to the Granma report, that result is due to the comprehensive and multidisciplinary approach of Cuban medicine.

Eduardo Alvarez, a second degree specialist in Endocrinology and member of the national technical commission advisor of Diabetes Mellitus at the Ministry of Public Health, told the daily that the prevention of this pandemic has gained strength, starting from local doctors offices and family clinics.

Alvarez said that achievements of the national program for care of the disease include diabetic centers where patients are educated on how to confront this disease.

For his part, Dr. Manuel Raices, of the Cuban Genetic Engineering and Biotechnology Center, stated that expanded use of Heberprot-P, a medicine for treating patients with diabetic foot ulcers, has shown notable results at 48 hospitals and more than 315 polyclinics.

More than 29,000 Cuban patients have benefited from the new vaccine, mainly in areas of primary health care. (Prensa Latina)